RSV

Respiratory syncytial virus (RSV) vaccination is approximately 77% to 81% effective against hospital and emergency department encounters among older adults, study finds.

Respiratory syncytial virus (RSV) caused significant hospitalizations and severe outcomes in adults, especially those aged 75 years and older.

The vaccine proved a cumulative efficacy of 62.9% against respiratory syncytial virus (RSV)-related lower respiratory tract disease in older adults over 3 seasons.

Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or influenza across Europe.

Study compares immediate post-discharge care requirements for respiratory syncytial virus (RSV), influenza, acute myocardial infarction, and stroke.

A new study highlights risk factors for hospitalization and severe illness among adults with respiratory syncytial virus (RSV) receiving care through the emergency department.

Survey reveals gaps in vaccination intentions for flu, COVID-19, respiratory syncytial virus, and pneumococcal disease.

A robust antibody response was found in patients in residents of long-term care facilities who were given the respiratory syncytial virus (RSV) vaccine.

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, hospitalizations, lost quality of life, and deaths, according to one study.

The first real-world study highlights benefits for adults aged 60 years and older who receive the respiratory syncytial virus (RSV) vaccine.

A new survey highlights lack of awareness about respiratory syncytial virus (RSV) among older adults, posing increased health risks for those with chronic conditions.

CDC’s Advisory Committee on Immunization Practices (ACIP) revises respiratory syncytial virus (RSV) vaccination guidelines to prioritize older adults and those at higher risk of severe disease.

New research highlights the increased risk of severe COVID-19 in individuals previously infected with respiratory syncytial virus (RSV).

Researchers estimate the financial impact of respiratory syncytial virus (RSV) in cardiorespiratory hospitalizations using MarketScan data and CDC viral positivity rates.

Efforts to regulate social media for youth face resistance; MK-1654 meets key goals in mid-to-late stage trial; active drug shortages remain above 300 for sixth consecutive quarter.

No increased risks of preterm birth or perinatal outcomes were identified with maternal vaccination status, according to one study.

Focusing on the diagnosis of RSV, Mary Bridgeman, PharmD, BCPS, BCGP, provides clinical insights on signs and symptoms and testing practices.

Knowledge on respiratory syncytial virus (RSV) risk factors may help inform public health authorities on high-risk populations, researchers suggest.

A panel of experts outline who’s at risk for RSV and how it’s spread, highlighting how transmission can be minimized.

Focusing on the economic burden of RSV, the panel discusses financial considerations for multiple patient populations, highlighting hospitalization costs and the main drivers of healthcare resource utilization.

Marty J. Feltner, PharmD, provides insights on complications associated with RSV infections and how complications vary for different patient populations.

A panel of experts on respiratory syncytial virus (RSV) introduce themselves and give an overview of patients who are most affected by RSV.

Vaccination against seasonal influenza and respiratory syncytial virus (RSV) in patients with high-risk heart failure was found safe with low incidence of mild adverse events (AEs).

The first respiratory syncytial virus (RSV) vaccine has been approved for adults aged 50 to 59 years who are at increased risk.

The FDA approved mRNA-1345, a Moderna vaccine for the treatment of respiratory syncytial virus (RSV). This single-dose vaccine offers protection against lower respiratory tract disease in adults over 60 years, with data suggesting long-term effectiveness.